INNOVUS PHARMA (OTCMKTS:INNV) on Focus After Report of More Shorts

February 14, 2018 - By reb123z

The stock of INNOVUS PHARMA (OTCMKTS:INNV) registered an increase of 55.96% in short interest. INNV’s total short interest was 34,000 shares in February as published by FINRA. Its up 55.96% from 21,800 shares, reported previously.

The stock increased 7.43% or $0.011 during the last trading session, reaching $0.159. About shares traded. Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. The company has market cap of $26.15 million. The Company’s products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. It currently has negative earnings. The firm also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence.

More notable recent Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) news were published by: Businesswire.com which released: “Innovus Pharma Enters Into License and Distribution Agreement with Acerus …” on January 08, 2018, also Seekingalpha.com with their article: “Innovus Pharmaceuticals’ (INNV) Bassam Damaj on Q2 2017 Results – Earnings …” published on August 15, 2017, Businesswire.com published: “Innovus Pharma Launches FlutiCareâ„¢ OTC Nasal Spray Allergy Relief in the US” on November 14, 2017. More interesting news about Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) were released by: Businesswire.com and their article: “Innovus Pharma Expands Its Sales Channels Through an Alliance with Wellmed, LP …” published on February 02, 2018 as well as Seekingalpha.com‘s news article titled: “Innovus Pharmaceuticals’ (INNV) Bassam Damaj on Q3 2017 Results – Earnings …” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.